Department of Surgery, Skåne University Hospital, Malmö, Sweden.
Institute of Clinical Sciences Malmö, Section of Surgery, Lund University, Lund, Sweden.
BJS Open. 2021 Jul 6;5(4). doi: 10.1093/bjsopen/zrab067.
Improvements in surgery, imaging, adjuvant treatment, and management of metastatic disease have led to modification of previous approaches regarding the risk of recurrence and prognosis in colorectal cancer. The aims of this study were to map patterns, risk factors, and the possibility of curative treatment of recurrent colorectal cancer in a multimodal setting.
This was a cohort study based on the COLOFOL trial population of patients who underwent radical resection of stage II or III colorectal cancer. The medical files of all patients with recurrence within 5 years after resection of the primary tumour were scrutinized. Follow-up time was 5 years after the first recurrence. Primary endpoints were cumulative incidence, site, timing, and risk factors for recurrence, and rate of potentially curative treatment. A secondary endpoint was survival.
Of 2442 patients, 471 developed recurrences. The 5-year cumulative incidence was 21.4 (95 per cent c.i. 19.5 to 23.3) per cent. The median time to detection was 1.1 years after surgery and 87.3 per cent were detected within 3 years. Some 98.2 per cent of patients who had potentially curative treatment were assessed by a multidisciplinary tumour board. A total of 47.8 per cent of the recurrences were potentially curatively treated. The 5-year overall survival rate after detection was 32.0 (95 per cent c.i. 27.9 to 36.3) per cent for all patients with recurrence, 58.6 (51.9 to 64.7) per cent in the potentially curatively treated group and 7.7 (4.8 to 11.5) per cent in the palliatively treated group.
Time to recurrence was similar to previous results, whereas the 21.4 per cent risk of recurrence was somewhat lower. The high proportion of patients who received potentially curative treatment, linked to a 5-year overall survival rate of 58.6 per cent, indicates that it is possible to achieve good results in recurrent colorectal cancer following multidisciplinary assessment.
手术、影像学、辅助治疗以及转移性疾病的管理水平的提高,使得人们对结直肠癌的复发风险和预后的认识发生了改变。本研究旨在多模式治疗背景下,对复发性结直肠癌的模式、危险因素和根治性治疗的可能性进行描绘。
本研究基于 COLOFOL 试验的队列研究人群,该人群接受了根治性手术切除 II 期或 III 期结直肠癌。所有术后 5 年内发生肿瘤复发的患者的病历资料都进行了详细审查。随访时间为首次复发后 5 年。主要终点为复发的累积发生率、部位、时间、危险因素以及潜在可治愈性治疗的比例。次要终点为生存情况。
在 2442 例患者中,471 例出现复发。5 年累积复发率为 21.4%(95%可信区间 19.5%至 23.3%)。中位复发时间为术后 1.1 年,87.3%的患者在 3 年内被发现。98.2%的潜在可治愈性治疗患者接受了多学科肿瘤委员会的评估。47.8%的复发病例接受了潜在可治愈性治疗。所有复发患者的 5 年总生存率为 32.0%(95%可信区间 27.9%至 36.3%),潜在可治愈性治疗组为 58.6%(51.9%至 64.7%),姑息性治疗组为 7.7%(4.8%至 11.5%)。
复发时间与既往结果相似,而 21.4%的复发风险略低。相当比例的患者接受了潜在可治愈性治疗,总 5 年生存率为 58.6%,这表明对复发性结直肠癌进行多学科评估,有可能获得良好的结果。